CN1166361C - 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂 - Google Patents

用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂 Download PDF

Info

Publication number
CN1166361C
CN1166361C CNB008116156A CN00811615A CN1166361C CN 1166361 C CN1166361 C CN 1166361C CN B008116156 A CNB008116156 A CN B008116156A CN 00811615 A CN00811615 A CN 00811615A CN 1166361 C CN1166361 C CN 1166361C
Authority
CN
China
Prior art keywords
piperidinyl
carbonyl
dihydro
dibromo
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008116156A
Other languages
English (en)
Chinese (zh)
Other versions
CN1370069A (zh
Inventor
亨利·杜兹
3
克劳斯·鲁道夫
沃尔夫冈·埃伯莱因
¡
沃尔夫哈德·恩格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1370069A publication Critical patent/CN1370069A/zh
Application granted granted Critical
Publication of CN1166361C publication Critical patent/CN1166361C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB008116156A 1999-08-10 2000-08-05 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂 Expired - Fee Related CN1166361C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937304.3 1999-08-10
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Publications (2)

Publication Number Publication Date
CN1370069A CN1370069A (zh) 2002-09-18
CN1166361C true CN1166361C (zh) 2004-09-15

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008116156A Expired - Fee Related CN1166361C (zh) 1999-08-10 2000-08-05 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂

Country Status (32)

Country Link
EP (1) EP1207884B1 (enExample)
JP (1) JP2003506403A (enExample)
KR (1) KR100713573B1 (enExample)
CN (1) CN1166361C (enExample)
AR (1) AR025078A1 (enExample)
AT (1) ATE281168T1 (enExample)
AU (1) AU777709B2 (enExample)
BG (1) BG65366B1 (enExample)
BR (1) BR0013009A (enExample)
CA (1) CA2378428C (enExample)
CZ (1) CZ300513B6 (enExample)
DE (2) DE19937304C2 (enExample)
EA (1) EA007531B1 (enExample)
EE (1) EE04928B1 (enExample)
ES (1) ES2231243T3 (enExample)
HK (1) HK1046854B (enExample)
HR (1) HRP20020117A2 (enExample)
HU (1) HUP0202397A3 (enExample)
IL (1) IL148057A (enExample)
MX (1) MXPA02001373A (enExample)
MY (1) MY129668A (enExample)
NO (1) NO20020605L (enExample)
NZ (1) NZ517367A (enExample)
PL (1) PL198483B1 (enExample)
PT (1) PT1207884E (enExample)
SK (1) SK285587B6 (enExample)
TR (1) TR200200359T2 (enExample)
TW (1) TWI285550B (enExample)
UA (1) UA73137C2 (enExample)
WO (1) WO2001010425A2 (enExample)
YU (1) YU8302A (enExample)
ZA (1) ZA200200997B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP1456198A1 (en) * 2001-12-12 2004-09-15 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1648466A1 (en) * 2003-07-07 2006-04-26 Boehringer Ingelheim International GmbH Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
EP1646611A1 (en) * 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009056A1 (fr) * 1995-09-07 1997-03-13 L'oreal Extrait d'iridacees et compositions le contenant
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
MXPA02001373A (es) 2002-07-30
CZ300513B6 (cs) 2009-06-03
NZ517367A (en) 2004-09-24
ATE281168T1 (de) 2004-11-15
BR0013009A (pt) 2002-04-30
HRP20020117A2 (en) 2003-10-31
PL364049A1 (en) 2004-12-13
EP1207884B1 (de) 2004-11-03
YU8302A (sh) 2004-12-31
EP1207884A2 (de) 2002-05-29
SK285587B6 (sk) 2007-04-05
UA73137C2 (en) 2005-06-15
BG106391A (bg) 2002-09-30
DE19937304C2 (de) 2003-08-21
IL148057A (en) 2008-04-13
KR100713573B1 (ko) 2007-05-02
PT1207884E (pt) 2004-12-31
CZ2002497A3 (cs) 2002-06-12
DE50008527D1 (de) 2004-12-09
TR200200359T2 (tr) 2002-05-21
ES2231243T3 (es) 2005-05-16
ZA200200997B (en) 2002-10-30
EE04928B1 (et) 2007-12-17
CA2378428C (en) 2009-10-20
BG65366B1 (bg) 2008-04-30
AU777709B2 (en) 2004-10-28
EA007531B1 (ru) 2006-10-27
HUP0202397A3 (en) 2006-07-28
IL148057A0 (en) 2002-09-12
NO20020605D0 (no) 2002-02-07
EA200200207A1 (ru) 2002-08-29
TWI285550B (en) 2007-08-21
CA2378428A1 (en) 2001-02-15
WO2001010425A2 (de) 2001-02-15
AR025078A1 (es) 2002-11-06
SK1972002A3 (en) 2002-06-04
HK1046854A1 (en) 2003-01-30
WO2001010425A3 (de) 2002-02-07
AU6992800A (en) 2001-03-05
NO20020605L (no) 2002-02-07
CN1370069A (zh) 2002-09-18
HK1046854B (zh) 2005-02-25
DE19937304A1 (de) 2001-03-15
MY129668A (en) 2007-04-30
KR20020016947A (ko) 2002-03-06
PL198483B1 (pl) 2008-06-30
EE200200061A (et) 2003-04-15
HUP0202397A2 (en) 2002-10-28
JP2003506403A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
HK1046854A1 (en) Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN1231467C (zh) 伤害感受蛋白受体orl－1的高亲合性配体，包含它们的药物组合物以及它们的用途
CN1178912C (zh) 旋转异构酶活性的小分子抑制剂
CN1232462A (zh) 毒蕈碱拮抗剂
CN1602196A (zh) 作为腺苷调节剂的2－氨基苯并噻唑脲
CN1788000A (zh) 酞嗪酮衍生物
HK1046102A1 (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1893952A (zh) 用于治疗移植排斥的吡咯并[2,3－d]嘧啶化合物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1483025A (zh) 化合物
CN1227547A (zh) 芳基链烷酰基哒嗪
CN1688581A (zh) [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂
CN1596258A (zh) 腺A2α受体拮抗剂
CN1501934A (zh) 新型的3-c(o)r取代的10-环己基苯甲酰基吡咯并苯并二氮杂�;保胎催产素受体拮抗剂
CN1093859C (zh) 新型吲哚－2,3－二酮－3－肟衍生物
CN1745077A (zh) 促旋酶抑制剂及其用途
CN1300281A (zh) 具有释放生长激素特性的化合物
CN1121806A (zh) 用于治疗呕吐的药剂
CN1030587A (zh) 2-(杂环烷基)咪唑并吡啶
CN1787821A (zh) 一种治疗焦虑症的方法
CN1543347A (zh) Bibn4096与其它抗偏头痛药物组合对治疗偏头痛的用途
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1921859A (zh) 用于治疗骨疾病的吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1046854

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040915

Termination date: 20100805